LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study

Coleman, R.L.; Lorusso, Domenica; Gennigens, Christine; González-Martín, Antonio; Randall, L.; Cibula, David; Lund, Bente; Woelber, Linn; Pignata, Salvatore Antonio; Forget, Fréd́eric; Redondo, A.; Rangwala, Reshma; Vindeløv, Signe Diness; Chen, M.; Harris, J.R.; Nicacio, Leonardo; Teng, Marita S.; Smith, M.; Monk, B.J.; Vergote, I.

doi:10.1016/j.annonc.2020.08.2262

Cited by 20 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some RECIST responses were recorded across several tumor types, with an ORR of 15.6% and remarkable activity in cervical cancer [ 110 ]. Accordingly, the phase II InnovaTV 204 [ 111 ] tested TV exclusively in patients with pretreated recurrent or metastatic CC (r/mCC) progressing to chemotherapy plus bevacizumab. Activity of TV was confirmed, with an ORR of 24%, a DCR of 72% and a median DOR of 8.3 months.…”

Section: Promising New Targets Under Investigationmentioning

confidence: 99%

Antibody–drug conjugates in solid tumors: a look into novel targets

2021

View full text Add to dashboard Cite

Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed to merge the selectivity of monoclonal antibodies with cell killing properties of chemotherapy. They are commonly described as the “Trojan Horses” of therapeutic armamentarium, because of their capability of directly conveying cytotoxic drug (payloads) into the tumor space, thus transforming chemotherapy into a targeted agent. Three novel ADCs have been recently approved, i.e., trastuzumab deruxtecan, sacituzumab govitecan and enfortumab vedotin, respectively, targeting HER2, Trop2 and Nectin4. Thanks to progressive advances in engineering technologies these drugs rely on, the spectrum of diseases sensitive to these drugs as well as their indications are in continuous expansion. Several novel ADCs are under evaluation, exploring new potential targets along with innovative payloads. This review aims at providing a summary of the technology behind these compounds and at presenting the latest ADCs approved in solid tumors, as well as at describing novel targets for ADCs under investigation and new strategies to optimize their efficacy in solid tumors.

show abstract

Section: Promising New Targets Under Investigationmentioning

confidence: 99%

Antibody–drug conjugates in solid tumors: a look into novel targets

2021

View full text Add to dashboard Cite

show abstract

“…In late September 2021, the FDA granted accelerated approval to Tivdak ® (tisotumab vedotin-tftv), deeming it the most recently approved ADC on the market. Tivdak ® , co-developed by Seagen and Genmab, is the first and only approved ADC indicated for treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy [ 111 , 112 ]. This is the third FDA approved ADC for Seagen, further cementing their dominance as the industry leader in ADC technologies.…”

Section: Fda Approved Adcsmentioning

confidence: 99%

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy

et al. 2021

View full text Add to dashboard Cite

The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has resulted in a significant market ‘boom’, garnering worldwide attention. Despite ADCs presenting huge challenges to researchers, particularly regarding the identification of a suitable combination of antibody, linker, and payload, as of September 2021, 11 ADCs have been granted FDA approval, with eight of these approved since 2017 alone. Optimism for this therapeutic approach is clear, despite the COVID-19 pandemic, 2020 was a landmark year for deals and partnerships in the ADC arena, suggesting that there remains significant interest from Big Pharma. Herein we review the enthusiasm for ADCs by focusing on the features of those approved by the FDA, and offer some thoughts as to where the field is headed.

show abstract

“…Immunotherapies and targeted therapies have been shown to improve survival in the recurrent setting. [259][260][261][262] However, there is limited information on the role of these therapies in the setting of HIV and no information on a survival benefit in HIV. Early phase clinical trials to assess safety are underway.…”

Section: Cancer Managementmentioning

confidence: 99%

Cervical cancer prevention and control in women living with human immunodeficiency virus

Castle

Einstein

Sahasrabuddhe

2021

CA A Cancer J Clinicians

122

View full text Add to dashboard Cite

Despite being highly preventable, cervical cancer is the fourth most common cancer and cause of cancer death in women globally. In low-income countries, cervical cancer is often the leading cause of cancer-related morbidity and mortality. Women living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome are at a particularly high risk of cervical cancer because of an impaired immune response to human papillomavirus, the obligate cause of virtually all cervical cancers. Globally, approximately 1 in 20 cervical cancers is attributable to HIV; in sub-Saharan Africa, approximately 1 in 5 cervical cancers is due to HIV. Here, the authors provide a critical appraisal of the evidence to date on the impact of HIV disease on cervical cancer risk, describe key methodologic issues, and frame the key outstanding research questions, especially as they apply to ongoing global efforts for prevention and control of cervical cancer. Expanded efforts to integrate HIV care with cervical cancer prevention and control, and vice versa, could assist the global effort to eliminate cervical cancer as a public health problem. CA Cancer

show abstract

LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study

Cited by 20 publications

References 0 publications

Antibody–drug conjugates in solid tumors: a look into novel targets

Antibody–drug conjugates in solid tumors: a look into novel targets

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy

Cervical cancer prevention and control in women living with human immunodeficiency virus

Contact Info

Product

Resources

About